treatment-related AEs occurred in 5/6 (83.3%) and 3/6 (50.0%), respectively
For Williams, staying power isnt just about career longevityits about embracing the tools that make it possible
This systematic review evaluates the efficacy, tolerability, and neurobiological rationale of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GLP-1/glucose-dependent insulinotropic peptide (GIP) agonists in treating nicotine use disorder (NUD), with particular attention to smoking abstinence, craving reduction, weight gain mitigation, and mechanistic insights
Distinguishing melanocytic nevi from melanoma by DNA copy number changes: comparative genomic hybridization as a research and diagnostic tool
Mohandes S, Doke T, Hu H, Mukhi D, Dhillon P, Susztak K (2023) Molecular pathways that drive diabetic kidney disease